Lionel Apetoh
  • E-mail :[email]
  • Phone : + 33 3 80 39 33 71
  • Location : Dijon, France
Last update 2016-10-22 16:26:32.357

Lionel Apetoh PhD Immunology

Course and current status

CURRENT SITUATION

  • 2016 -   ERC Team leader, INSERM UMR866, Dijon, France.

Research focus: “Cell intrinsic control of CD4 T cell differentiation by cytosolic DNA sensing pathways

  • 2012 -   Chargé de recherche de 1ère classe (Research assistant professor in immunology), INSERM UMR866, Dijon, France. 

POSITIONS

  • 2011-2015  Group leader in Pr. Ghiringhelli’s laboratory, INSERM UMR866, Dijon, France.

Research focus: “CD4 T cell differentiation and cancer”

  • 2008-2010 Postdoctoral research fellow at the Brigham and Womens’ Hospital, Harvard Medical School, Boston, MA, United States

Research project: “Transcriptional regulation of CD4 type 1 regulatory T cells”

Supervisor: Pr Vijay Kuchroo 

  • 2004-2008  PhD in immunology (summa cum laude) defended June 3rd 2008 in Villejuif, France. 

Research project: “Immunogenicity of tumor cell death triggered by anticancer therapies”

PhD Supervisor: Pr Laurence Zitvogel

Scientific summary

Our group currently investigates the relationships between CD4 T lymphocytes and anticancer immune responses.

Effector CD4 T cells were initially classified in 1986 by Mossman and Coffman into Th1 and Th2 cells.  Th1 cells limit infections caused by intracellular bacteria while parasitic infections favor Th2 cell expansion. In the setting of cancer immunity, Th1 cell polarization is associated with an effective anticancer immune response in contrast to Th2 cell immunity, which possibly contributes to tumor growth. Novel subsets of CD4 T lymphocytes have now been identified like Th17 cells (secreting IL-17) and Th9 cells (secreting IL-9). These cells are known to be highly proinflammatory in vivo. However, their putative contribution to tumor progression remains incompletely defined. Our group aims to determine the molecular mechanisms that can endow Th17 and Th9 cells with anticancer properties to contemplate the use of these cells in anticancer adoptive T cell therapy.

Team involved in this project :

  • Apetoh Lionel (Research assistant professor in immunology)
  • Rivera Vargas Thaiz (Post-doc)
  • Humblin Etienne (PhD student)
  • Benoit-Lizon Isis (PhD student)
  • Roussey Aurélie (Research assistant)
  • Martin Tiffany (Research assistant)
  • Mélis Andréa (Technician)

 

Selected publications (out of 85):

  • F Vegran, H Berger, R Boidot, G Mignot, M Bruchard, M Dosset, F Chalmin, C Rébé, V Dérangère, B Ryffel, M Kato, A Prévost-Blondel, F Ghiringhelli, L Apetoh 

IRF1 dictates the IL-21-dependent anticancer functions of Th9 cells. Nat. Immunol., 2014 Aug;15(8):758-66.

  • H Berger, F Végran, M Chikh, F Gilardi, S Ladoire, H Bugaut, G Mignot, F Chalmin, M Bruchard, V Derangère, A Chevriaux, C Rébé, C Pot, B Ryffel, A Hichami, B Desvergnes, F Ghiringhelli, L Apetoh

SOCS3 transactivation by PPARg prevents IL-17-driven cancer growth. Cancer Res. , 2013 Jun 15;73(12):3578-90.

  • M Bruchard, G Mignot, V Derangère, F Chalmin, A Chevriaux, F Végran, W Boireau, B Simon, B Ryffel, JL Connat, J Kanellopoulos, F Martin, C Rébé, L Apetoh*, F Ghiringhelli*

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the NLRP3 inflammasome and promotes tumor growth. Nat. Med., 2013 Jan;19(1):57-64.* Contributed equally

  • L Apetoh, FJ Quintana, C Pot, N Joller, S Xiao, D Kumar, EJ Burns, DH Sherr, HL Weiner, VK Kuchroo

The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2010 Sep;11(9):854-61.

  • L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, MC Maiuri, E Ullrich, P Saulnier, H Yang, S Amigorena, B Ryffel, FJ Barrat, P Saftig, F Levi, R Lidereau, C Nogues, JP Mira, A Chompret, V Joulin, F Clavel-Chapelon, J Bourhis, F André, S Delaloge, T Tursz, G Kroemer and  L Zitvogel

Toll-like Receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007 Sep:13(9):1050-1059.

Image d’exemple